3-甲磺酰氨基苯硼酸 | 148355-75-3

• 物质功能分类: 原料药 - 人工合成抗感染类药 - 磺胺类药及增效剂
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-甲磺酰氨基苯硼酸
• 中文别名: 3-(甲基磺酰胺基)苯硼酸；3-甲基磺酰氨基苯基硼酸
• 英文名称: 3-(methylsulfonamido)phenylboronic acid
• 英文别名: 3-(methylsulfonylamino)phenylboronic acid；3-(methanesulfonylamino)phenylboronic acid；3-(methylsulfonylylamino)phenylboronic acid；(3-methylsulfonylaminobenzene)boronic acid；(3-methanesulfonamidophenyl)boronic acid；[3-(methanesulfonamido)phenyl]boronic acid
• CAS: 148355-75-3
• 化学式: C₇H₁₀BNO₄S
• mdl: MFCD02179478
• 分子量: 215.038
• InChiKey: XUIQQIRLFMCWLN-UHFFFAOYSA-N

物化性质

• 熔点：
  90-96°C
• 沸点：
  433.7±55.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.15
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  95
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2935009090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Methylsulfonylaminophenylboronic acid
Synonyms: 3-Methanesulfonylaminophenylboronic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Methylsulfonylaminophenylboronic acid
CAS number: 148355-75-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H10BNO4S
Molecular weight: 215.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲磺酰氨基苯硼酸 在 N-氯代丁二酰亚胺 、 copper(l) chloride 作用下， 以 乙腈 为溶剂， 反应 2.0h， 以93%的产率得到N-(3-chlorophenyl)methanesulfonamide
  参考文献：
  名称：

  10.1021/0l9029337

  摘要：

  DOI：

  10.1021/0l9029337

文献信息

• 1-Amino 1H-imidazoquinolines
  申请人：Griesgraber W. George

  公开号：US20050054640A1

  公开（公告）日：2005-03-10

  1-Amino 1H-imidazoquinoline compounds, pharmaceutical compositions containing the compounds, intermediates, and methods of making and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

  1-氨基1H-咪唑喹啉化合物，含有该化合物的药物组合物，中间体，以及制备这些化合物的方法和将这些化合物用作免疫调节剂的方法，用于调节动物体内细胞因子生物合成，并用于治疗包括病毒性和肿瘤性疾病在内的疾病。
• [EN] BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS<br/>[FR] DERIVES DE BENZOFURANE UTILISES POUR TRAITER DES TROUBLES HYPERPROLIFERANTS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005014566A1

  公开（公告）日：2005-02-17

  The invention relates to novel heterocycles of formula (I), processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.

  这项发明涉及到式(I)的新异环化合物，以及用于制备这些化合物的方法，以及它们用于制备治疗或预防疾病的药物，特别是治疗过度增殖性疾病的药物。
• HETEROCYCLIC ANTIVIRAL COMPOUNDS
  申请人：Chin Elbert

  公开号：US20100081658A1

  公开（公告）日：2010-04-01

  Compounds having the formula I wherein R 1 , R 2a , R 2b , R 2c , R 3 , Y and p are as defined herein and C2-C3 is a single or double bond are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

  具有以下公式的化合物 I，其中 R1、R2a、R2b、R2c、R3、Y 和 p 的定义如本文所述，且 C2-C3 是单键或双键的化合物是丙型肝炎病毒NS5b聚合酶抑制剂。还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
• [EN] N-CONTAINING HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES À TENEUR EN N
  申请人：CYTOPIA RES PTY LTD

  公开号：WO2009062258A1

  公开（公告）日：2009-05-22

  The present invention relates to N-containing heterocyclic compounds that are inhibitors of protein kinases including JAK kinases. In particular, the compounds are selective for JAK1, JAK2, JAK3 or TYK2 kinases and combinations thereof such as JAK1 and JAK2. The kinase inhibitors can be used in the treatment of kinase associated diseases such as immunological and inflammatory diseases including organ transplants; hyperproliferative diseases including cancer and myeloproliferative diseases; viral diseases; metabolic diseases; and vascular diseases.

  本发明涉及N-含杂环化合物，其为包括JAK激酶在内的蛋白激酶的抑制剂。特别是，这些化合物对JAK1、JAK2、JAK3或TYK2激酶及其组合物如JAK1和JAK2具有选择性。激酶抑制剂可用于治疗与激酶相关的疾病，如免疫性和炎性疾病，包括器官移植；增生性疾病，包括癌症和骨髓增生性疾病；病毒性疾病；代谢性疾病；以及血管性疾病。
• Discovery of a series of 1H-pyrrolo[2,3-b]pyridine compounds as potent TNIK inhibitors
  作者：Bowen Yang、Qian Wu、Xiajuan Huan、Yingqing Wang、Yin Sun、Yueyue Yang、Tongchao Liu、Xin Wang、Lin Chen、Bing Xiong、Dongmei Zhao、Zehong Miao、Danqi Chen

  DOI：10.1016/j.bmcl.2020.127749

  日期：2021.2

  In an in-house screening, 1H-pyrrolo[2,3-b]pyridine scaffold was found to have high inhibition on TNIK. Several series of compounds were designed and synthesized, among which some compounds had potent TNIK inhibition with IC50 values lower than 1 nM. Some compounds showed concentration-dependent characteristics of IL-2 inhibition. These results provided new applications of TNIK inhibitors and new prospects

  在内部筛选中，发现1 H-吡咯并[2,3- b ]吡啶支架对TNIK具有高度抑制作用。设计并合成了一系列化合物，其中一些化合物具有强的TNIK抑制作用，IC 50值低于1 nM。一些化合物表现出浓度依赖性的IL-2抑制特性。这些结果提供了TNIK抑制剂的新应用以及TNIK作为药物靶标的新前景。

表征谱图